260 related articles for article (PubMed ID: 31479631)
41. Hot Spot Analysis of YAP-TEAD Protein-Protein Interaction Using the Fragment Molecular Orbital Method and Its Application for Inhibitor Discovery.
Kim J; Lim H; Moon S; Cho SY; Kim M; Park JH; Park HW; No KT
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439400
[TBL] [Abstract][Full Text] [Related]
42. The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.
Furet P; Bordas V; Le Douget M; Salem B; Mesrouze Y; Imbach-Weese P; Sellner H; Voegtle M; Soldermann N; Chapeau E; Wartmann M; Scheufler C; Fernandez C; Kallen J; Guagnano V; Chène P; Schmelzle T
ChemMedChem; 2022 Oct; 17(19):e202200303. PubMed ID: 35950546
[TBL] [Abstract][Full Text] [Related]
43. The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment.
Mokhtari RB; Ashayeri N; Baghaie L; Sambi M; Satari K; Baluch N; Bosykh DA; Szewczuk MR; Chakraborty S
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444578
[TBL] [Abstract][Full Text] [Related]
44. Discovery of Covalent Inhibitors Targeting the Transcriptional Enhanced Associate Domain Central Pocket.
Karatas H; Akbarzadeh M; Adihou H; Hahne G; Pobbati AV; Yihui Ng E; Guéret SM; Sievers S; Pahl A; Metz M; Zinken S; Dötsch L; Nowak C; Thavam S; Friese A; Kang C; Hong W; Waldmann H
J Med Chem; 2020 Oct; 63(20):11972-11989. PubMed ID: 32907324
[TBL] [Abstract][Full Text] [Related]
45. Regulation of the Hippo Pathway Transcription Factor TEAD.
Lin KC; Park HW; Guan KL
Trends Biochem Sci; 2017 Nov; 42(11):862-872. PubMed ID: 28964625
[TBL] [Abstract][Full Text] [Related]
46. Rational design and chemical modification of TEAD coactivator peptides to target hippo signaling pathway against gastrointestinal cancers.
Gao S; Wang Y; Ji L
J Recept Signal Transduct Res; 2021 Aug; 41(4):408-415. PubMed ID: 32912021
[TBL] [Abstract][Full Text] [Related]
47. Study of the TEAD-binding domain of the YAP protein from animal species.
Mesrouze Y; Bokhovchuk F; Meyerhofer M; Zimmermann C; Fontana P; Erdmann D; Chène P
Protein Sci; 2021 Feb; 30(2):339-349. PubMed ID: 33146905
[TBL] [Abstract][Full Text] [Related]
48. Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity.
Gridnev A; Maity S; Misra JR
Front Oncol; 2022; 12():1021823. PubMed ID: 36523977
[TBL] [Abstract][Full Text] [Related]
49. The evolutionary history of YAP and the hippo/YAP pathway.
Hilman D; Gat U
Mol Biol Evol; 2011 Aug; 28(8):2403-17. PubMed ID: 21415026
[TBL] [Abstract][Full Text] [Related]
50. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
[TBL] [Abstract][Full Text] [Related]
51. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of
Tang TT; Konradi AW; Feng Y; Peng X; Ma M; Li J; Yu FX; Guan KL; Post L
Mol Cancer Ther; 2021 Jun; 20(6):986-998. PubMed ID: 33850002
[TBL] [Abstract][Full Text] [Related]
52. Synthetic molecules targeting yes associated protein activity as chemotherapeutics against cancer.
Iftikhar R; Zahoor AF; Irfan M; Rasul A; Rao F
Chem Biol Drug Des; 2021 Dec; 98(6):1025-1037. PubMed ID: 34587361
[TBL] [Abstract][Full Text] [Related]
53. Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.
Mélin L; Abdullayev S; Fnaiche A; Vu V; González Suárez N; Zeng H; Szewczyk MM; Li F; Senisterra G; Allali-Hassani A; Chau I; Dong A; Woo S; Annabi B; Halabelian L; LaPlante SR; Vedadi M; Barsyte-Lovejoy D; Santhakumar V; Gagnon A
ChemMedChem; 2021 Oct; 16(19):2982-3002. PubMed ID: 34164919
[TBL] [Abstract][Full Text] [Related]
54. Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.
Sellner H; Chapeau E; Furet P; Voegtle M; Salem B; Le Douget M; Bordas V; Groell JM; Le Goff AL; Rouzet C; Wietlisbach T; Zimmermann T; McKenna J; Brocklehurst CE; Chène P; Wartmann M; Scheufler C; Kallen J; Williams G; Harlfinger S; Traebert M; Dumotier BM; Schmelzle T; Soldermann N
ChemMedChem; 2023 Jun; 18(11):e202300051. PubMed ID: 36988034
[TBL] [Abstract][Full Text] [Related]
55. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
[TBL] [Abstract][Full Text] [Related]
56. YAP/TAZ-TEAD activity promotes the malignant transformation of cervical intraepithelial neoplasia through enhancing the characteristics and Warburg effect of cancer stem cells.
Li S; Li X; Yang YB; Wu SF
Apoptosis; 2024 Mar; ():. PubMed ID: 38553612
[TBL] [Abstract][Full Text] [Related]
57. Leveraging Advanced In Silico Techniques in Early Drug Discovery: A Study of Potent Small-Molecule YAP-TEAD PPI Disruptors.
Awoonor-Williams E; Dickson CJ; Furet P; Golosov AA; Hornak V
J Chem Inf Model; 2023 Apr; 63(8):2520-2531. PubMed ID: 37010474
[TBL] [Abstract][Full Text] [Related]
58. Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity.
Kimura M; Horie T; Baba O; Ide Y; Tsuji S; Ruiz Rodriguez R; Watanabe T; Yamasaki T; Otani C; Xu S; Miyasaka Y; Nakashima Y; Kimura T; Ono K
EMBO Rep; 2020 Apr; 21(4):e48389. PubMed ID: 32147946
[TBL] [Abstract][Full Text] [Related]
59. Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface.
Gibault F; Coevoet M; Sturbaut M; Farce A; Renault N; Allemand F; Guichou JF; Drucbert AS; Foulon C; Magnez R; Thuru X; Corvaisier M; Huet G; Chavatte P; Melnyk P; Bailly F; Cotelle P
Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29738494
[TBL] [Abstract][Full Text] [Related]
60. Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation.
Canu V; Donzelli S; Sacconi A; Lo Sardo F; Pulito C; Bossel N; Di Benedetto A; Muti P; Botti C; Domany E; Bicciato S; Strano S; Yarden Y; Blandino G
Cell Death Differ; 2021 May; 28(5):1493-1511. PubMed ID: 33230261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
